{"protocolSection": {"identificationModule": {"nctId": "NCT00777946", "orgStudyIdInfo": {"id": "CSPA100A2303"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients Not Adequately Responding to Aliskiren Alone", "officialTitle": "A Randomized, Eight-week Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren / Amlodipine (300/5 mg and 300/10 mg) in Comparison With Aliskiren 300 mg in Patients With Essential Hypertension Not Adequately Responsive to Aliskiren 300 mg Monotherapy"}, "statusModule": {"statusVerifiedDate": "2011-06", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-10"}, "primaryCompletionDateStruct": {"date": "2009-05", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-05", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-10-20", "studyFirstSubmitQcDate": "2008-10-21", "studyFirstPostDateStruct": {"date": "2008-10-22", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-12-13", "resultsFirstSubmitQcDate": "2011-05-13", "resultsFirstPostDateStruct": {"date": "2011-06-15", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2011-06-30", "lastUpdatePostDateStruct": {"date": "2011-07-12", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "External Affairs", "oldOrganization": "Novartis"}, "leadSponsor": {"name": "Novartis", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This study will assess the safety and efficacy of combination aliskiren/amlodipine in patients not adequately controlled with aliskiren alone"}, "conditionsModule": {"conditions": ["Hypertension"], "keywords": ["Aliskiren, Amlodipine, Non-responder to aliskiren"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 818, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Aliskiren 300 mg/Amlodipine 5 mg", "type": "EXPERIMENTAL", "description": "Participants received 1 Aliskiren/Amlodipine 300/5mg tablet + 1 Placebo to Aliskiren tablet once daily in the morning for 8 weeks.", "interventionNames": ["Drug: Aliskiren/Amlodipine 300/5 mg", "Drug: Placebo to Aliskiren"]}, {"label": "Aliskiren 300 mg/Amlodipine 10 mg", "type": "EXPERIMENTAL", "description": "Participants received 1 Aliskiren/Amlodipine 300/10 mg tablet + 1 Placebo to Aliskiren tablet orally once daily in the morning for 8 weeks.", "interventionNames": ["Drug: Aliskiren/Amlodipine 300/10 mg", "Drug: Placebo to Aliskiren"]}, {"label": "Aliskiren 300 mg", "type": "ACTIVE_COMPARATOR", "description": "Participants received 1 Aliskiren 300 mg tablet + 1 Placebo to Aliskiren/Amlodipine tablet orally once daily in the morning for 8 weeks.", "interventionNames": ["Drug: Aliskiren 300 mg", "Drug: Placebo to Aliskiren/Amlodipine"]}], "interventions": [{"type": "DRUG", "name": "Aliskiren 300 mg", "description": "Aliskiren 300 mg tablet taken orally once a day with a glass of water.", "armGroupLabels": ["Aliskiren 300 mg"]}, {"type": "DRUG", "name": "Aliskiren/Amlodipine 300/5 mg", "description": "Aliskiren/Amlodipine 300/5 mg tablet taken orally once a day with a glass of water.", "armGroupLabels": ["Aliskiren 300 mg/Amlodipine 5 mg"]}, {"type": "DRUG", "name": "Aliskiren/Amlodipine 300/10 mg", "description": "Aliskiren/Amlodipine 300/10 mg taken orally once a day with a glass of water.", "armGroupLabels": ["Aliskiren 300 mg/Amlodipine 10 mg"]}, {"type": "DRUG", "name": "Placebo to Aliskiren", "description": "Placebo to Aliskiren tablet taken orally once a day.", "armGroupLabels": ["Aliskiren 300 mg/Amlodipine 10 mg", "Aliskiren 300 mg/Amlodipine 5 mg"]}, {"type": "DRUG", "name": "Placebo to Aliskiren/Amlodipine", "description": "Placebo to Aliskiren/Amlodipine taken orally once a day.", "armGroupLabels": ["Aliskiren 300 mg"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline to End of Study in the Mean Sitting Diastolic Blood Pressure (msDBP)", "description": "After the patient had been sitting for 5 minutes, systolic and diastolic blood pressures were measured 3 times using the automatic Blood Pressure monitor and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit. The difference of the msDBP at baseline from the msDBP at 8 weeks was calculated using an Analysis of Covariance (ANCOVA) model with baseline as a covariate and treatment and region as two factors.", "timeFrame": "Baseline, End of Study (Week 8)"}], "secondaryOutcomes": [{"measure": "Change From Baseline to End of Study in the Mean Sitting Systolic Blood Pressure (msSBP)", "description": "After the patient had been sitting for 5 minutes, systolic and diastolic blood pressures were measured 3 times using the automatic Blood Pressure monitor and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit. The difference of the msSBP at baseline from the msSBP at 8 weeks was calculated using an ANCOVA model with baseline as a covariate and treatment and region as two factors.", "timeFrame": "Baseline, End of Study (Week 8)"}, {"measure": "Number of Participants With Serious Adverse Events and Adverse Events", "description": "The number of participants with any Serious Adverse Event and the number of participants with Adverse Events in any system organ class.\n\nAdditional information about Adverse Events can be found in the Adverse Event Section.", "timeFrame": "8 weeks"}, {"measure": "Percentage of Participants Achieving Blood Pressure Control", "description": "After the patient had been sitting for 5 minutes, with the back supported and both feet placed on the floor, systolic and diastolic blood pressures were measured 3 times using the automatic Blood Pressure monitor and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit.\n\nBlood Pressure control was defined as having a mean sitting Diastolic Blood Pressure \\<90 and a mean sitting Systolic Blood Pressure \\<140.", "timeFrame": "8 weeks"}, {"measure": "Percentage of Participants Achieving a Diastolic Blood Pressure Response", "description": "After the patient had been sitting for 5 minutes, with the back supported and both feet placed on the floor, systolic and diastolic blood pressures were measured 3 times using the automatic Blood Pressure monitor and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit.\n\nA Diastolic Blood Pressure Response was defined as a mean sitting Diastolic Blood Pressure (msDBP) \\<90 mmHg or a \u2265 10 mmHg reduction in msDBP from baseline.", "timeFrame": "8 weeks"}, {"measure": "Percentage of Participants Achieving a Systolic Blood Pressure Response", "description": "After the patient had been sitting for 5 minutes, with the back supported and both feet placed on the floor, systolic and diastolic blood pressures were measured 3 times using the automatic Blood Pressure monitor and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit.\n\nA Systolic Blood Pressure Response was defined as a mean sitting Systolic Blood Pressure (msSBP) \\<140 mmHg or a \u2265 20 mmHg reduction in msSBP from baseline.", "timeFrame": "8 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Newly diagnosed patients or patients who have not been treated for hypertension within the 4 weeks prior to Visit 1 must have a mean sitting Diastolic Blood Pressure (msDBP) \u2265 95 mmHg and \\< 110 mmHg at Visits 1 and 2\n* Patients who have been treated for hypertension within the 4 weeks prior to - Visit 1 must have a msDBP \u2265 90 mmHg and \\< 110 mmHg at Visit 2\n* All patients must have a msDBP \u2265 90 mmHg and \\< 110 mmHg at Visit 4\n\nExclusion Criteria:\n\n* Severe hypertension\n* Pregnant or nursing (lactating) women\n* Women of child-bearing potential\n* Previous or current diagnosis of heart failure New York Heart Association (NYHA Class II-IV)\n* Serum potassium \u2265 5.3 mEq/L (mmol/L) at Visit 1\n* Uncontrolled Type 1 or Type 2 diabetes mellitus\n* Hypersensitivity to renin inhibitors, calcium channel blockers, or to drugs with Similar chemical structures\n* History of hypertensive encephalopathy or cerebrovascular accident, or history of transient ischemic attack (TIA), myocardial infarction, coronary bypass surgery, or any percutaneous coronary intervention\n\nOther protocol-defined inclusion/exclusion criteria may apply.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis", "affiliation": "Novartis", "role": "STUDY_CHAIR"}], "locations": [{"facility": "Investigative site", "city": "Estonia", "country": "Estonia"}, {"facility": "Investigative site", "city": "France", "country": "France"}, {"facility": "Investigative Site", "city": "Iceland", "country": "Iceland"}, {"facility": "Investigative Site", "city": "India", "country": "India"}, {"facility": "Investigative site", "city": "Italy", "country": "Italy"}, {"facility": "Investigative Site", "city": "Republic of Korea", "country": "Korea, Republic of"}, {"facility": "Investigative Site", "city": "Lithuania", "country": "Lithuania"}, {"facility": "Investigative Site", "city": "Spain", "country": "Spain"}, {"facility": "Investigative Site", "city": "Venezuela", "country": "Venezuela"}]}, "referencesModule": {"references": [{"pmid": "22303910", "type": "DERIVED", "citation": "Glorioso N, Thomas M, Troffa C, Argiolas G, Patel S, Baek I, Zhang J. Antihypertensive efficacy and tolerability of aliskiren/amlodipine single- pill combinations in patients with an inadequate response to aliskiren monotherapy. Curr Vasc Pharmacol. 2012 Nov;10(6):748-55. doi: 10.2174/157016112803520765."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "This study consisted of a 7 day wash-out period and a 4 week single-blind run-in period prior to the 8 week double-blind period.\n\n2 of the 820 randomized patients were randomized in error, are not included in the 818 participants enrolled in the double-blind period, did not receive study drug \\& are not included in the Safety and Full Analysis Sets.", "groups": [{"id": "FG000", "title": "Aliskiren 300 mg/Amlodipine 10 mg", "description": "Participants received 1 Aliskiren/Amlodipine 300/10mg tablet + 1 Placebo to Aliskiren tablet once daily in the morning for 8 weeks."}, {"id": "FG001", "title": "Aliskiren 300 mg/Amlodipine 5 mg", "description": "Participants received 1 Aliskiren/Amlodipine 300/5mg tablet + 1 Placebo to Aliskiren tablet once daily in the morning for 8 weeks."}, {"id": "FG002", "title": "Aliskiren 300 mg", "description": "Participants received 1 Aliskiren 300 mg tablet + 1 Placebo to Aliskiren/Amlodipine tablet orally once daily in the morning for 8 weeks."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "1 patient in the Aliskiren 300 mg/Amlodipine 10 mg group was randomized in error.", "numSubjects": "283"}, {"groupId": "FG001", "comment": "1 patient in the Aliskiren 300 mg/Amlodipine 5 mg group was randomized in error.", "numSubjects": "277"}, {"groupId": "FG002", "numSubjects": "260"}]}, {"type": "Safety & Full Analysis Sets", "achievements": [{"groupId": "FG000", "numSubjects": "282"}, {"groupId": "FG001", "numSubjects": "276"}, {"groupId": "FG002", "numSubjects": "260"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "262"}, {"groupId": "FG001", "numSubjects": "271"}, {"groupId": "FG002", "numSubjects": "244"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "21"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "16"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "3"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "9"}]}, {"type": "Condition no longer required study drug", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Patient withdrew consent", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "3"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Protocol deviation", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Randomized in error", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Aliskiren 300 mg/Amlodipine 10 mg", "description": "Participants received 1 Aliskiren/Amlodipine 300/10mg tablet + 1 Placebo to Aliskiren tablet once daily in the morning for 8 weeks."}, {"id": "BG001", "title": "Aliskiren 300 mg/Amlodipine 5 mg", "description": "Participants received 1 Aliskiren/Amlodipine 300/5mg tablet + 1 Placebo to Aliskiren tablet once daily in the morning for 8 weeks."}, {"id": "BG002", "title": "Aliskiren 300 mg", "description": "Participants received 1 Aliskiren 300 mg tablet + 1 Placebo to Aliskiren/Amlodipine tablet orally once daily in the morning for 8 weeks."}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "283"}, {"groupId": "BG001", "value": "277"}, {"groupId": "BG002", "value": "260"}, {"groupId": "BG003", "value": "820"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "54.6", "spread": "10.67"}, {"groupId": "BG001", "value": "54.4", "spread": "10.69"}, {"groupId": "BG002", "value": "54.7", "spread": "10.99"}, {"groupId": "BG003", "value": "54.6", "spread": "10.77"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "120"}, {"groupId": "BG001", "value": "101"}, {"groupId": "BG002", "value": "103"}, {"groupId": "BG003", "value": "324"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "163"}, {"groupId": "BG001", "value": "176"}, {"groupId": "BG002", "value": "157"}, {"groupId": "BG003", "value": "496"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline to End of Study in the Mean Sitting Diastolic Blood Pressure (msDBP)", "description": "After the patient had been sitting for 5 minutes, systolic and diastolic blood pressures were measured 3 times using the automatic Blood Pressure monitor and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit. The difference of the msDBP at baseline from the msDBP at 8 weeks was calculated using an Analysis of Covariance (ANCOVA) model with baseline as a covariate and treatment and region as two factors.", "populationDescription": "Full Analysis Set (all randomized patients who received study drug). Three patients (1 in Aliskiren 300 mg/Amlodipine 10 mg group and 2 in the Aliskiren 300 mg/Amlodipine 5 mg group were excluded from the analysis due to lack of post-baseline assessment.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline, End of Study (Week 8)", "groups": [{"id": "OG000", "title": "Aliskiren 300 mg/Amlodipine 10 mg", "description": "Participants received 1 Aliskiren/Amlodipine 300/10mg tablet + 1 Placebo to Aliskiren tablet once daily in the morning for 8 weeks."}, {"id": "OG001", "title": "Aliskiren 300 mg/Amlodipine 5 mg", "description": "Participants received 1 Aliskiren/Amlodipine 300/5mg tablet + 1 Placebo to Aliskiren tablet once daily in the morning for 8 weeks."}, {"id": "OG002", "title": "Aliskiren 300 mg", "description": "Participants received 1 Aliskiren 300 mg tablet + 1 Placebo to Aliskiren/Amlodipine tablet orally once daily in the morning for 8 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "281"}, {"groupId": "OG001", "value": "274"}, {"groupId": "OG002", "value": "260"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-13.07", "spread": "0.463"}, {"groupId": "OG001", "value": "-10.54", "spread": "0.467"}, {"groupId": "OG002", "value": "-5.84", "spread": "0.480"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to End of Study in the Mean Sitting Systolic Blood Pressure (msSBP)", "description": "After the patient had been sitting for 5 minutes, systolic and diastolic blood pressures were measured 3 times using the automatic Blood Pressure monitor and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit. The difference of the msSBP at baseline from the msSBP at 8 weeks was calculated using an ANCOVA model with baseline as a covariate and treatment and region as two factors.", "populationDescription": "Full Analysis Set (all randomized patients who received study drug). Three patients (1 in Aliskiren 300 mg/Amlodipine 10 mg group and 2 in the Aliskiren 300 mg/Amlodipine 5 mg group were excluded from the analysis due to lack of post-baseline assessment.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline, End of Study (Week 8)", "groups": [{"id": "OG000", "title": "Aliskiren 300 mg/Amlodipine 10 mg", "description": "Participants received 1 Aliskiren/Amlodipine 300/10mg tablet + 1 Placebo to Aliskiren tablet once daily in the morning for 8 weeks."}, {"id": "OG001", "title": "Aliskiren 300 mg/Amlodipine 5 mg", "description": "Participants received 1 Aliskiren/Amlodipine 300/5mg tablet + 1 Placebo to Aliskiren tablet once daily in the morning for 8 weeks."}, {"id": "OG002", "title": "Aliskiren 300 mg", "description": "Participants received 1 Aliskiren 300 mg tablet + 1 Placebo to Aliskiren/Amlodipine tablet orally once daily in the morning for 8 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "281"}, {"groupId": "OG001", "value": "274"}, {"groupId": "OG002", "value": "260"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-18.04", "spread": "0.780"}, {"groupId": "OG001", "value": "-14.43", "spread": "0.788"}, {"groupId": "OG002", "value": "-6.42", "spread": "0.809"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Serious Adverse Events and Adverse Events", "description": "The number of participants with any Serious Adverse Event and the number of participants with Adverse Events in any system organ class.\n\nAdditional information about Adverse Events can be found in the Adverse Event Section.", "populationDescription": "Safety Population consisted of all randomized participants who received study drug.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Aliskiren 300 mg/Amlodipine 10 mg", "description": "Participants received 1 Aliskiren/Amlodipine 300/10mg tablet + 1 Placebo to Aliskiren tablet once daily in the morning for 8 weeks."}, {"id": "OG001", "title": "Aliskiren 300 mg/Amlodipine 5 mg", "description": "Participants received 1 Aliskiren/Amlodipine 300/5mg tablet + 1 Placebo to Aliskiren tablet once daily in the morning for 8 weeks."}, {"id": "OG002", "title": "Aliskiren 300 mg", "description": "Participants received 1 Aliskiren 300 mg tablet + 1 Placebo to Aliskiren/Amlodipine tablet orally once daily in the morning for 8 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "282"}, {"groupId": "OG001", "value": "276"}, {"groupId": "OG002", "value": "260"}]}], "classes": [{"title": "Serious Adverse Events", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "4"}, {"groupId": "OG002", "value": "1"}]}]}, {"title": "Adverse Events", "categories": [{"measurements": [{"groupId": "OG000", "value": "85"}, {"groupId": "OG001", "value": "80"}, {"groupId": "OG002", "value": "59"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants Achieving Blood Pressure Control", "description": "After the patient had been sitting for 5 minutes, with the back supported and both feet placed on the floor, systolic and diastolic blood pressures were measured 3 times using the automatic Blood Pressure monitor and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit.\n\nBlood Pressure control was defined as having a mean sitting Diastolic Blood Pressure \\<90 and a mean sitting Systolic Blood Pressure \\<140.", "populationDescription": "Full Analysis Set (all randomized patients who received study drug). Three patients (1 in Aliskiren 300 mg/Amlodipine 10 mg group and 2 in the Aliskiren 300 mg/Amlodipine 5 mg group were excluded from the analysis due to lack of post-baseline assessment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Aliskiren 300 mg/Amlodipine 10 mg", "description": "Participants received 1 Aliskiren/Amlodipine 300/10mg tablet + 1 Placebo to Aliskiren tablet once daily in the morning for 8 weeks."}, {"id": "OG001", "title": "Aliskiren 300 mg/Amlodipine 5 mg", "description": "Participants received 1 Aliskiren/Amlodipine 300/5mg tablet + 1 Placebo to Aliskiren tablet once daily in the morning for 8 weeks."}, {"id": "OG002", "title": "Aliskiren 300 mg", "description": "Participants received 1 Aliskiren 300 mg tablet + 1 Placebo to Aliskiren/Amlodipine tablet orally once daily in the morning for 8 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "281"}, {"groupId": "OG001", "value": "274"}, {"groupId": "OG002", "value": "260"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "65.5"}, {"groupId": "OG001", "value": "56.5"}, {"groupId": "OG002", "value": "31.5"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants Achieving a Diastolic Blood Pressure Response", "description": "After the patient had been sitting for 5 minutes, with the back supported and both feet placed on the floor, systolic and diastolic blood pressures were measured 3 times using the automatic Blood Pressure monitor and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit.\n\nA Diastolic Blood Pressure Response was defined as a mean sitting Diastolic Blood Pressure (msDBP) \\<90 mmHg or a \u2265 10 mmHg reduction in msDBP from baseline.", "populationDescription": "Full Analysis Set (all randomized patients who received study drug). Three patients (1 in Aliskiren 300 mg/Amlodipine 10 mg group and 2 in the Aliskiren 300 mg/Amlodipine 5 mg group were excluded from the analysis due to lack of post-baseline assessment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Aliskiren 300 mg/Amlodipine 10 mg", "description": "Participants received 1 Aliskiren/Amlodipine 300/10mg tablet + 1 Placebo to Aliskiren tablet once daily in the morning for 8 weeks."}, {"id": "OG001", "title": "Aliskiren 300 mg/Amlodipine 5 mg", "description": "Participants received 1 Aliskiren/Amlodipine 300/5mg tablet + 1 Placebo to Aliskiren tablet once daily in the morning for 8 weeks."}, {"id": "OG002", "title": "Aliskiren 300 mg", "description": "Participants received 1 Aliskiren 300 mg tablet + 1 Placebo to Aliskiren/Amlodipine tablet orally once daily in the morning for 8 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "281"}, {"groupId": "OG001", "value": "274"}, {"groupId": "OG002", "value": "260"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "83.6"}, {"groupId": "OG001", "value": "77.7"}, {"groupId": "OG002", "value": "51.5"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants Achieving a Systolic Blood Pressure Response", "description": "After the patient had been sitting for 5 minutes, with the back supported and both feet placed on the floor, systolic and diastolic blood pressures were measured 3 times using the automatic Blood Pressure monitor and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit.\n\nA Systolic Blood Pressure Response was defined as a mean sitting Systolic Blood Pressure (msSBP) \\<140 mmHg or a \u2265 20 mmHg reduction in msSBP from baseline.", "populationDescription": "Full Analysis Set (all randomized patients who received study drug). Three patients (1 in Aliskiren 300 mg/Amlodipine 10 mg group and 2 in the Aliskiren 300 mg/Amlodipine 5 mg group were excluded from the analysis due to lack of post-baseline assessment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Aliskiren 300 mg/Amlodipine 10 mg", "description": "Participants received 1 Aliskiren/Amlodipine 300/10mg tablet + 1 Placebo to Aliskiren tablet once daily in the morning for 8 weeks."}, {"id": "OG001", "title": "Aliskiren 300 mg/Amlodipine 5 mg", "description": "Participants received 1 Aliskiren/Amlodipine 300/5mg tablet + 1 Placebo to Aliskiren tablet once daily in the morning for 8 weeks."}, {"id": "OG002", "title": "Aliskiren 300 mg", "description": "Participants received 1 Aliskiren 300 mg tablet + 1 Placebo to Aliskiren/Amlodipine tablet orally once daily in the morning for 8 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "281"}, {"groupId": "OG001", "value": "274"}, {"groupId": "OG002", "value": "260"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "77.2"}, {"groupId": "OG001", "value": "69.7"}, {"groupId": "OG002", "value": "43.8"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "8 weeks", "description": "Safety set (all patients who received at least 1 dose of double-blind study drug).", "eventGroups": [{"id": "EG000", "title": "Aliskiren 300 mg/Amlodipine 10 mg", "description": "Participants received 1 Aliskiren/Amlodipine 300/10mg tablet + 1 Placebo to Aliskiren tablet once daily in the morning for 8 weeks.", "seriousNumAffected": 3, "seriousNumAtRisk": 282, "otherNumAffected": 26, "otherNumAtRisk": 282}, {"id": "EG001", "title": "Aliskiren 300 mg/Amlodipine 5 mg", "description": "Participants received 1 Aliskiren/Amlodipine 300/5mg tablet + 1 Placebo to Aliskiren tablet once daily in the morning for 8 weeks.", "seriousNumAffected": 4, "seriousNumAtRisk": 276, "otherNumAffected": 6, "otherNumAtRisk": 276}, {"id": "EG002", "title": "Aliskiren 300 mg", "description": "Participants received 1 Aliskiren 300 mg tablet + 1 Placebo to Aliskiren/Amlodipine tablet orally once daily in the morning for 8 weeks.", "seriousNumAffected": 1, "seriousNumAtRisk": 260, "otherNumAffected": 1, "otherNumAtRisk": 260}], "seriousEvents": [{"term": "Vertigo", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 282}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 276}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 260}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 282}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 276}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 260}]}, {"term": "Drug hypersensitivity", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 282}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 276}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 260}]}, {"term": "Lobar pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 282}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 276}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 260}]}, {"term": "Viral infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 282}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 276}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 260}]}, {"term": "Post-traumatic pain", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 282}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 276}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 260}]}, {"term": "Road traffic accident", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 282}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 276}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 260}]}, {"term": "Intervertebral disc protrusion", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 282}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 276}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 260}]}, {"term": "Lung neoplasm malignant", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 282}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 276}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 260}]}, {"term": "Chronic obstructive pulmonary disease", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 282}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 276}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 260}]}], "otherEvents": [{"term": "Oedema peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 26, "numAtRisk": 282}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 276}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 260}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01", "removedCountries": ["South Africa"]}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M1470", "name": "Essential Hypertension", "relevance": "LOW"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017311", "term": "Amlodipine"}, {"id": "C000446481", "term": "Aliskiren"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000092502", "term": "Renin Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M352589", "name": "Aliskiren", "asFound": "Distribution", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M2932", "name": "Renin Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}